← Back to Screener
BiomX Inc. (PHGE)
Price$0.72
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-91.41%
Price vs S&P 500 (4W)14.84%
VGM Score2.89
Market Capitalization$7.31M
All Metrics
Book Value / Share (Quarterly)$7.43
P/TBV (Annual)1.10x
Cash Flow / Share (Quarterly)$-3.53
Price vs S&P 500 (YTD)-69.66%
EPS (TTM)$-24.74
10-Day Avg Trading Volume10.55M
EPS Excl Extra (TTM)$-24.74
EPS (Annual)$-22.19
ROI (Annual)-73.41%
Cash / Share (Quarterly)$0.18
ROA (Last FY)-625.96%
EBITD / Share (TTM)$-16.17
ROE (5Y Avg)-237.19%
Cash Flow / Share (Annual)$-16.56
P/B Ratio0.70x
P/B Ratio (Quarterly)1.34x
Net Income / Employee (Annual)$-1,809,900
Net Interest Coverage (TTM)-22.79x
ROA (TTM)-260.36%
EPS Incl Extra (Annual)$-22.19
Current Ratio (Annual)0.87x
Quick Ratio (Quarterly)0.51x
3-Month Avg Trading Volume4.12M
52-Week Price Return-92.27%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.11
52-Week High$14.71
EPS Excl Extra (Annual)$-22.19
CapEx CAGR (5Y)-71.20%
26-Week Price Return-83.49%
Quick Ratio (Annual)0.82x
13-Week Price Return-87.48%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.24x
Enterprise Value$6.14M
Book Value / Share Growth (5Y)46.87%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.74
3-Month Return Std Dev288.09%
Net Income / Employee (TTM)$-2,384,000
ROE (Last FY)-73.41%
Net Interest Coverage (Annual)-41.03x
EPS Basic Excl Extra (Annual)$-22.19
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-24.74
ROI (TTM)-190.95%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$12.65
Price vs S&P 500 (52W)-116.63%
Year-to-Date Return-61.50%
5-Day Price Return-30.77%
EPS Normalized (Annual)$-22.19
ROA (5Y Avg)-176.03%
Month-to-Date Return-42.86%
Cash Flow / Share (TTM)$-0.58
EBITD / Share (Annual)$-24.04
LT Debt / Equity (Annual)1.75x
ROI (5Y Avg)-89.30%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-24.74
P/TBV (Quarterly)1.67x
P/B Ratio (Annual)0.55x
Book Value / Share (Annual)$25.24
Price vs S&P 500 (13W)-95.73%
Beta1.32x
Revenue / Share (TTM)$0.00
ROE (TTM)-190.95%
52-Week Low$0.36
mGradeF
vgmGradeF
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.00
4.00
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PHGEBiomX Inc. | — | — | F | $0.72 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
BiomX develops personalized phage-based treatments for chronic bacterial infections using its proprietary BOLT platform to customize phage cocktails against specific pathogens. The company's pipeline includes BX004 for pseudomonas infections in cystic fibrosis patients and BX211 for diabetic foot osteomyelitis, addressing significant unmet needs where traditional antibiotics face efficacy challenges.